Article
Prevalence of gyrA, gyrB, parC, and parE mutations in clinical isolates of Streptococcus pneumoniae with decreased susceptibilities to different fluoroquinolones and originating from Worldwide Surveillance Studies during the 1997-1998 respiratory season.
Antimicrobial agents and chemotherapy - 1 Feb 2000
Jones M E, Sahm D F, Martin N, Scheuring S, Heisig P, Thornsberry C, Köhrer K, Schmitz F J
Abstract excerpt
From 8,419 worldwide clinical isolates of Streptococcus pneumoniae obtained during 1997-1998, 69 isolates with reduced susceptibility or resistance to fluoroquinolones (FQs) were molecularly characterized. For the isolates in this prevalence study, only parC (Ser-79-->Tyr) and gyrA (Ser-81-->Phe or Tyr) mutations, especially in combination, were found to contribute significantly to resistance. These mutations...
Topics
- Anti-Infective Agents
- Bacterial Proteins
- DNA Gyrase
- DNA Topoisomerase IV
- DNA Topoisomerases, Type II
- DNA-Binding Proteins
- Drug Resistance, Microbial
- Fluoroquinolones
- Gene Frequency